-+ 0.00%
-+ 0.00%
-+ 0.00%

Abbisko unit Abbisko Therapeutics doses first patient in Phase I trial of pan-KRAS inhibitor ABSK211

PUBT·08/31/2026 07:16:07
Listen to the news
Abbisko unit Abbisko Therapeutics doses first patient in Phase I trial of pan-KRAS inhibitor ABSK211
  • Abbisko Cayman’s unit Abbisko Therapeutics dosed the first patient in a Phase I trial of pan-KRAS inhibitor ABSK211.
  • Study targets advanced solid tumors with KRAS alterations, tracking safety, tolerability, efficacy, pharmacokinetics.
  • ABSK211 is an oral small-molecule candidate with IND clearance from China’s NMPA and the US FDA.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12307549), on August 31, 2026, and is solely responsible for the information contained therein.